



INTUITIONLABS / RESEARCH & PRACTICAL GUIDANCE

Japan's Drug Approval Process: A Guide to PMDA & MHLW

Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.

Published by IntuitionLabs · 2025-10-27 · japan drug approval process · pmda · mhlw · pharmaceutical regulation · drug lag · sakigake designation · pmd act · regulatory affairs japan

Original article: <https://intuitionlabs.ai/articles/japan-drug-approval-process>



In this article

1. Japan's Drug Approval Process: A Guide to PMDA & MHLW
 2. Executive Summary
 3. Introduction and Historical Background
 4. Regulatory Framework in Japan
 5. Legislative Basis and Agencies
 6. Regulatory Targets
 7. Approvals and Post-Marketing Control
 8. The Drug Development and Approval Process
 9. Preclinical and Planning
 10. Clinical Trials (IND Phase)
 11. New Drug Application Submission (NDA)
 12. Regulatory Review and Decision
 13. Expedited and Special Approval Pathways
 14. Regulatory Timelines and Statistical Analysis
 15. Clinical Trial Environment and Considerations
 16. Infrastructure and Workforce
 17. Role of SMOs and CROs
 18. Cost and Patient Recruitment
 19. Specific Challenges
 20. Case Studies and Real-World Examples
 21. Alzheimer's Disease – Lecanemab (Leqembi)
 22. Oncology – Gilteritinib and Pembrolizumab
 23. Rare Disease – Viltolarsen (Duchenne Muscular Dystrophy)
 24. Emerging Therapies and Other Modalities
 25. Discussion of Challenges and Implications
 26. Persistent Drug Lag and Loss
 27. Balancing Speed and Safety
 28. Harmonization and Global Development
 29. Future Directions
 30. Conclusion
 31. References
-

Japan's Drug Approval Process: A Guide to PMDA & MHLW

Executive Summary

The **drug approval process** in Japan has evolved dramatically over the past two decades to balance rigorous safety standards with timely patient access to medications. The **Pharmaceuticals and Medical Devices Agency (PMDA)** serves as Japan's primary regulatory review body, evaluating new drug applications for safety, efficacy, and quality, while the **Ministry of Health, Labour and Welfare (MHLW)** grants final marketing authorizations based on PMDA reports ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) (www.pmda.go.jp). In the 2000s, Japan faced a notorious “drug lag” (delays behind U.S. and Europe) that impeded access to novel therapies. Through major reforms and resource investments, Japan has reduced review times to near parity with other regions; by 2019 the median review time for new drugs was **304 days** (compared to 243 days at FDA and 423 days at EMA ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov))). Nevertheless, disparities persist in certain fields (notably neurology and psychiatry) where approvals continue to lag due to small domestic markets and development challenges ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)).

To incentivize innovation, Japan has implemented multiple expedited pathways. The **SAKIGAKE designation** (launched 2015) fast-tracks first-in-world therapies by targeting a 6-month review (www.mhlw.go.jp), provided the drug is novel, addresses a serious need, and is submitted first in Japan ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) (www.mhlw.go.jp). The **Conditional Early Approval System** (legislated in 2019, effective 2020) permits provisional approval for drugs treating serious illnesses when **confirmatory trials** are impractical ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Japan's **Orphan Drug program** (≤50,000 patients) offers R&D subsidies, priority consultations, tax credits, and extended exclusivity to promote therapies for rare diseases (www.mhlw.go.jp) (www.mhlw.go.jp). Other incentives include **priority review** (9-month target review for therapies with no alternatives) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) and pediatric-development planning requirements.

Recent reforms in 2024–2025 further aim to accelerate approvals. MHLW relaxed Japan-only **clinical data** requirements via a new guideline (Dec 2023) that generally waives the mandatory Japanese Phase I study if foreign data show comparable safety ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) (www.clinicaltrialsarena.com). The 2025 amendments to the PMD Act strengthen quality and supply controls (new compliance officers, supply stability managers) and expand R&D support: the conditional approval system will include drugs based on early evidence (insightplus.bakermckenzie.com), pediatric development plans are mandated (insightplus.bakermckenzie.com), and a fund for innovative drug research is created (insightplus.bakermckenzie.com).

Data illustrate the outcome of these efforts. From 2008–2019, Japan approved 400 new active substances (NAS), of which 20% were world-first approvals ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). The median drug lag has sharply declined (from 4.3 years in 2008–11 to 1.3 years by 2016–19) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). In FY2024–25 alone, PMDA granted 148 approval decisions (66 for new active ingredients) (pharmaboardroom.com) across leading therapy areas (metabolic, oncology, autoimmunity, etc.).

Nevertheless, as of March 2024, about 82 innovations remain “lost” to Japan (never submitted, down marginally from 86 in 2023) and 53 have notable lags (as reported by JPMA/MHLW) (www.tokyofoundation.org), driven by factors such as past pricing policies, small startup presence, and unique regulatory burdens (e.g. historic local data requirements, prescription limits) (www.tokyofoundation.org) (www.clinicaltrialsarena.com). MHLW has responded with active outreach, publicly calling for sponsors to develop eight designated “drug loss” products after failing to find developers through direct requests (pj.jiho.jp). Additionally, PMDA moved to full-scale implementation of eCTD v4.0 electronic submissions from April 2026 (japan.freyrsolutions.com).

This report provides an in-depth examination of Japan’s drug approval process. We analyze its history and legal framework, the detailed registration steps, review timelines, and the array of expedited pathways. We integrate statistical analyses and case examples (e.g. recent [Alzheimer’s](#) and cancer drug approvals) to illustrate regulatory performance. Finally, we discuss the strategic and clinical implications, including efforts to further harmonize globally and to overcome persistent challenges such as drug lag and cost hurdles. This comprehensive review draws on regulatory documents, peer-reviewed analyses, and industry reports to present a nuanced, evidence-based picture of Japan’s evolving pharmaceutical approval landscape.

Introduction and Historical Background

Japan is one of the world’s largest [pharmaceutical markets](#), making its drug approval environment crucial for innovation and healthcare. Historically, Japan’s regulatory system was conservative: before the 1990s, patient access to new medicines lagged significantly behind the United States and Europe, a phenomenon dubbed the “drug lag” (pmc.ncbi.nlm.nih.gov) (www.tokyofoundation.org). Concerns grew in the 2000s that Japan’s stringent development requirements – including mandated Japanese clinical data – and extended review times delayed treatments for patients. Recognizing this, Japanese authorities progressively reformed the system to better balance **safety with timely access**.

The legal basis of Japan’s regulation dates back to the **Pharmaceutical Affairs Law (Yakuji-hō)** of 1948, which established broad controls over drug safety and distribution. Over decades, this law was updated multiple times. A landmark change occurred in **2004** with the formation of the **Pharmaceuticals and Medical Devices Agency (PMDA)** (www.pmda.go.jp). The PMDA amalgamated earlier independent bodies (e.g. the Pharmaceuticals and Medical Devices Evaluation Center formed in 1997 (www.mhlw.go.jp)) to provide a centralized, corporate-style reviewing authority. This freed the Ministry of Health, Labour and Welfare (MHLW) to focus on policy and final authorization. In 2004, PMDA began conducting scientific reviews of new drug applications, after which MHLW formally grants marketing approval (pmc.ncbi.nlm.nih.gov) (www.pmda.go.jp). In **2014**, a major overhaul renamed the Pharmaceutical Affairs Law as the **Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices** (often called the **Pharmaceuticals and Medical Devices Act**, PMD Act) (monolith.law), explicitly expanding its scope to include regenerative medicine and gene therapies. This law’s Article 1 underscores its objective: to “improve public health by regulating the quality, efficacy, and safety” of drugs, medical devices, cosmetics, and regenerative products (monolith.law).

Japan was an original member of the **International Council for Harmonisation (ICH)**, aligning its standards with global norms. Over time, Japan adopted ICH guidelines for clinical trials and quality. For example, the ICH E5 guideline (1998) on ethnic factors began allowing foreign clinical data to support Japanese approvals. More recently, Japan has issued guidelines to facilitate **multiregional clinical trials (MRCTs)** and encourage global development. These steps have been crucial in reducing unnecessary duplication of trials in Japanese patients. Nevertheless, until 2023, the PMDA often insisted on at least a Japanese Phase I study before joining a global trial (to verify safety/PK) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). This requirement, aimed at protection of Japanese participants, contributed to drug lag by slowing trial start and submissions.

In parallel with review reforms, the **clinical trial system itself** underwent reforms. Historically, any trial to support an NDA (called *Chiken*) required Japanese GCP compliance, and investigators at each site were de facto co-sponsors (a unique feature of Japanese GCP ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov))). Additionally, academic and early trials had been regulated by non-binding Ethical Guidelines until a new **Clinical Trials Act (CTA)** came into effect in 2018 ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). The CTA imposed a legally mandated review process (certified review boards), transparency requirements, and reporting to a public registry. These changes, prompted by misconduct cases, aimed to raise overall trial quality but also increased administrative burdens for investigators ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)).

The Japanese regulatory journey reflects a steady shift: from an isolated, cautious system to one more integrated with global practices. Reforms in the 2010s – including **priority review pathways, SME support**, and staffing increases at PMDA – have shortened approval times. Still, recent commentary highlights concerns about Japan's **economic attractiveness** for innovation. Market share has fallen (from ~25% of world pharma in the 1980s to ~4.4% by 2023 (www.tokyofoundation.org)). This decline is attributed to pricing policies (aggressive post-listing cuts), as well as persistent regulatory hurdles (e.g. “2-week rule” on prescriptions, extra data requirements) that render Japan a lower priority for some sponsors (www.tokyofoundation.org) (www.tokyofoundation.org). Stakeholders have coined “drug loss” (assets never submitted) and “drug lag” to describe this issue (www.tokyofoundation.org) (www.tokyofoundation.org). MHLW and PMDA have responded with targeted initiatives (discussed below) to reverse these trends.

This report examines Japan's drug approval framework in detail: the legal and organizational structure, step-by-step approval procedures, effect of recent reforms, and statistical outcomes. Throughout, we cite official sources and studies to ensure an evidence-based analysis of how Japan seeks both to protect patients and to foster rapid development of safe, effective new medicines.

Regulatory Framework in Japan

Legislative Basis and Agencies

The **Pharmaceuticals and Medical Devices Act (PMD Act)** is the foundational law governing drug regulation in Japan. Its purpose is to ensure that pharmaceuticals are “safe, effective, and of assured quality” while also promoting necessary research and development (monolith.law). The Act empowers MHLW and PMDA to set standards for manufacturing, clinical trials, and marketing authorization. Under this Act, both **pharmaceuticals** and **medical devices** (and regenerative products) are regulated in an integrated manner.

Two government bodies share responsibilities:

- **Pharmaceuticals and Medical Devices Agency (PMDA)**. Established April 2004 by consolidating earlier agencies (www.pmda.go.jp), PMDA is an *independent administrative agency* (a government-affiliated corporation) that conducts scientific reviews of drug applications. PMDA is analogous to the FDA in its review role. It also handles pre-submission consultations, post-marketing safety surveillance coordination, and provides guidance on regulatory science. PMDA has specialized review divisions (e.g. New Drugs I–V, Vaccine/Blood, Cellular Products) for different therapeutic areas (pmc.ncbi.nlm.nih.gov).
- **Ministry of Health, Labour and Welfare (MHLW)**. MHLW is the cabinet ministry that holds ultimate legal authority. After PMDA completes a review (the *shinsa*), MHLW formally grants marketing authorization. MHLW also sets policies on pricing and reimbursement, enforces post-market actions (recalls, warnings), and issues ministerial notifications implementing new regulatory systems (e.g. orphan drug designation criteria).

Historically, the former Ministry of Health and Welfare ran drug review in-house. A pre-1997 reorganization introduced specialized review teams (“Pharmaceuticals and Medical Devices Evaluation Center” in 1997 (www.mhlw.go.jp)). Later reforms (2004) created PMDA to further professionalize and speed up review. PMDA’s independent status (remunerated partly by user fees from industry) helped expand its reviewer staff and expertise, contributing to faster reviews (median approval times have since dropped markedly (pmc.ncbi.nlm.nih.gov) (www.clinicaltrialsarena.com)).

Regulatory Targets

The PMD Act covers a broad array of products (monolith.law). Relevant definitions include:

- **“Pharmaceuticals”**: Medicines for diagnosis, treatment, or prevention of disease (excluding equipment), as well as those listed in Japanese Pharmacopoeia (monolith.law). This includes both prescription and many over-the-counter drugs.
- **“Medical Devices”**: Instruments or apparatus intended for medical use, ranging from bandages to complex machines. Devices are classified (Class I–IV) with varying review levels.
- **“Regenerative Medical Products”**: Introduced in the 2014 revision, this category includes gene therapies (in vivo or ex vivo), cell therapies, and tissue-engineered products (excluding organ transplants and blood products) (pmc.ncbi.nlm.nih.gov).

The Act also defines **“designated drugs”** (narcotics, stimulants, etc.) subject to stricter controls on use and distribution, although these have separate handling outside the standard approval process.

Under the PMD Act and its ordinances, numerous requirements are specified:

- **Good Manufacturing Practice (GMP)**: Factories must be inspected and licensed for GMP before production of ethical (prescription) drugs. Manufacturing changes often require regulatory approval.

- **Good Clinical Practice (GCP):** Clinical trials for registration must follow Japanese GCP, which aligns with ICH-GCP standards. (Japanese GCP has unique aspects: for investigator-initiated trials, each site's principal investigator is the legal sponsor, and hospital directors share responsibility ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)).)
- **Labeling and Advertising:** Strict rules govern drug labeling and healthcare claims. All claims must be supported by approved indications, and even cosmetic or food products must be careful not to make drug-like claims (monolith.law).

Compliance with these rules is enforced by MHLW inspections and penalties. Historically, safety scandals (e.g. HIV-tainted blood products, lawsuits in the 1990s (www.mhlw.go.jp)) spurred stronger enforcement and regulatory tightening.

Approvals and Post-Marketing Control

When a new drug is ready for submission, the sponsor (domestic or foreign company) files a **New Drug Application (NDA)** with MHLW, supplying a **Common Technical Document (CTD)** dossier. PMDA conducts a thorough review of the chemistry, manufacturing controls (CMC), pharmacology/toxicology data, and clinical trial results. After the scientific review (which now includes Medical Officer comments, inspections, and sometimes advisory committees), PMDA issues a recommendation. Finally, the MHLW Minister issues the marketing authorization (the *shonin*) based on that recommendation.

Once approved, a drug is listed under Japan's universal National Health Insurance, typically within 2–3 months, enabling reimbursement (www.clinicaltrialsarena.com). Post-approval, the product enters a *re-examination period* (a post-marketing period in which efficacy and safety are re-confirmed; it is not a pricing mechanism) of up to 10 years for orphan drugs (www.mhlw.go.jp). During this time, PMDA monitors safety through mandatory post-market surveillance and periodic surveys (known as *all-case surveillance* or *special use-condition surveys*) for certain products. MHLW can direct marketing authorization holders to issue safety communications ("Blue Letters" and "Yellow Letters") if new risks arise. Label changes, re-examination data, and post-marketing studies are used during this time to confirm real-world efficacy and safety.

Before moving on to detailed steps, it is important to emphasize Japan's evolving approach to international harmonization. Membership in ICH means that guidelines like E3 (CTD format), E6 (GCP), and E8 (general considerations) apply. Japan also participates in international regulatory-science initiatives and is pursuing digital transformation of regulation. Such collaboration is intended to streamline simultaneous global development.

The Drug Development and Approval Process

The journey from compound discovery to Japanese approval involves multiple phases, combining global development elements and Japan-specific steps. Below we outline each major phase and their Japanese context.

Preclinical and Planning

Before human trials, sponsors prepare preclinical data (toxicology, pharmacology) largely according to international standards. In the planning stage, companies often engage in **PMDA consultations** to guide acceptable study designs and endpoints. The PMDA offers official scientific advice programs (including early “Consultations on Clinical Trial Protocols” and “Review Consultations”) which can help align global development plans with Japanese requirements. While not mandatory, these consultations can clarify data expectations and avoid later delays.

For products first developed abroad, a key early consideration is whether Japanese subjects will be required. Traditionally, Japan has insisted on data in Japanese populations (sometimes via a small bridging study) in case of known ethnic differences ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)) (www.tokyofoundation.org). However, guidance from late 2023 now states that an extra Japanese Phase I trial *is not always necessary* before enrolling Japanese patients in global trials, provided existing data adequately justify safety and PK profiles ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)) (www.clinicaltrialsarena.com). This change, intended to reduce “drug loss,” still requires case-by-case justification and may lead to smaller bridging cohort strategies within broader trials.

Clinical Trials (IND Phase)

In Japan, initiating a clinical trial requires submitting a **Clinical Trial Notification (CTN)** to the MHLW/PMDA, rather than seeking an “investigational new drug (IND)” approval as in the U.S. The CTN includes the trial protocol, investigator qualifications, details of investigational products, and contracting institutions. For registration-directed trials (called *Chiken*), sponsors (including now qualified academic investigators ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/))) must also register under Japanese GCP. After PMDA receives the CTN, there is a 30-day review period during which any concerns must be resolved. If no issues are raised, the trial may commence ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)).

Japan's clinical trial landscape has unique features. A network of **Site Management Organizations (SMOs)** plays a critical role: many hospitals and clinics contract with SMOs to manage trials. SMOs provide trained coordinators, consent support, regulatory documentation, and patient recruitment assistance (www.clinicaltrialsarena.com). This arose because Japan historically lacked centralized trial sites and because physicians abroad may not have bandwidth for research. In fact, about 70% of Japanese trial sites involve SMOs (www.clinicaltrialsarena.com). Data show SMO involvement shortens the time to first patient enrollment (an average of 110 days from study initiation with SMO involvement versus 130 days without) (www.clinicaltrialsarena.com).

Registering clinical trials in public databases (the Japan Registry of Clinical Trials, *JRCT*) became mandatory in recent years. Likewise, institutional ethics committees (now often transitioning toward centralized IRBs) review and approve each site's participation. These processes, introduced under the 2018 Clinical Trials Act ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)), aim to ensure ethical oversight and transparency. However, they have also increased administrative load on investigators, as discussed later.

New Drug Application Submission (NDA)

Once sufficient clinical data (typically Phase I–III trials) are available, the sponsor compiles a **NDA dossier** in CTD format (Modules 1–5) and submits it to MHLW. A typical J-NDA includes Japanese-language components for Module 1 (administrative info, labeling) and Modules 2–5 (overviews, summaries, and data) mostly in English. Until 2024, Modules 1–2 had to be in Japanese, but **from September 2024**, PMDA now accepts those sections in English if the sponsor has no Japanese affiliate (www.clinicaltrialsarena.com), simplifying global sponsorship.

The NDA dossier covers: chemical/pharmaceutical data (CMC), nonclinical pharmacology/toxicology, and clinical trial reports (Japan-specific and global data). For drugs that have already been marketed abroad, applications may be classified as new indications, new dosage forms, or new formulations, but still require local review. Generic and biosimilar filings follow separate abridged paths (GMP/license data with emphasis on bioequivalence), which are beyond our scope here.

During submission, sponsors can request **priority review** status if the drug addresses a serious condition with no standard therapy (or for certain orphan drugs) (pmc.ncbi.nlm.nih.gov). For a new molecular entity meeting those criteria, PMDA aims to complete review in **approximately 9 months** (compared to 12 months for standard review) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Otherwise, standard review takes up to 12 months (though actual median times have recently been shorter, as noted earlier).

Regulatory Review and Decision

Once submitted, PMDA conducts a scientific review. This usually involves medical officers, chemists, statisticians, and other reviewers examining all aspects of the data. If issues arise, PMDA may issue deficiency letters (requests for clarification or additional data) and schedule pre-approval inspections of manufacturing sites or clinical sites. The review process can include advisory committee meetings for contentious cases, but this is not routine for every application.

PMDA uses a “*team review*” model: specialists in various fields jointly deliberate (a change instituted in 1997 (www.mhlw.go.jp)). This is supplemented by consultation partners (outside experts) for highly novel cases. Importantly, PMDA now works to published review-time targets; these targets have driven median review time down from years in the past to under a year in recent practice (www.clinicaltrialsarena.com).

At the end of review, PMDA issues a report summarizing its conclusions (essentially *recommendation*). The MHLW Minister then officially grants the marketing authorization (in Japanese, “shonin”) based on that report. This is generally a formality – MHLW overturns PMDA’s recommendations only in rare cases. Upon authorization, PMDA also notifies the sponsor of any conditions of approval (e.g. mandated post-marketing studies or risk-management plans).

Japan’s **post-marketing commitments** are stringent. As a condition of approval, the agency often requires “all-case surveillance” for certain products (collecting data on every treated patient for a period), risk management plans (including timely labeling revisions), and formal re-examination studies (usually completed by the end of a 6–10 year re-examination period). New safety findings can lead to urgent communications (“Blue Letters” for rapid communications) or label changes.

The overall sequence – from IND to NDA to approval – can be summarized as follows:

1. **Preclinical Development** (Research, nonclinical studies).
2. **Consultations** (PMDA scientific advice, protocol meetings).
3. **Clinical Trial Notification (CTN) & Start of Trials** (Phase I/II/III).
4. **Investigational New Drug (Registration-Directed) Trials (Chicken)** under GCP.
5. **Data Analysis** and finalization of dossier.
6. **NDA Submission** to MHLW (Modules 1–5, CTD format).
7. **Review** by PMDA (up to ~1 year; priority option ~9 months).
8. **Inspection** of manufacturing and sites (as needed).
9. **Approval (Shonin)** issued by MHLW + price listing negotiation.
10. **Post-Marketing Surveillance** and Re-examination.

(See Table 1 below for a comparison of review timelines and criteria with US/EU systems.)

Regulatory Authority	Review Category	Target Approval Time	Key Criteria
United States (FDA)	Priority Review	8 months (standard 12) (pmc.ncbi.nlm.nih.gov)	Significantly improve safety/effectiveness; serious disease (pmc.ncbi.nlm.nih.gov)
European Union (EMA)	Accelerated Assmnt	~150 days (standard 210) (pmc.ncbi.nlm.nih.gov)	Public health importance; unmet need; strong evidence (pmc.ncbi.nlm.nih.gov)
Japan (PMDA/MHLW)	Priority Review	9 months (standard 12) (pmc.ncbi.nlm.nih.gov)	No existing therapy or superior benefit; serious/orphan (pmc.ncbi.nlm.nih.gov)
Japan (MHLW)	Conditional Approval	9 months (priority review applies) (pmc.ncbi.nlm.nih.gov) (insightplus.bakermckenzie.com)	Serious disease; proven utility; confirmatory trials difficult; reasonable efficacy prospect (pmc.ncbi.nlm.nih.gov)
Japan (MHLW)	SAKIGAKE	6 months (half standard) (www.mhlw.go.jp)	New MOA; serious indication; prominent effect; first submitted in Japan (pmc.ncbi.nlm.nih.gov)

Table 1: Comparison of expedited review pathways in Japan versus the US and EU. ‘Conditional approval for drugs’ refers to Japan’s drug conditional-approval system; it is not Japan’s separate conditional-and-time-limited approval scheme for regenerative medical products.

Expedited and Special Approval Pathways

To reduce drug lag and address unmet needs, Japan provides several **facilitated regulatory pathways**. These complement the standard NDA process by accelerating review or lowering data requirements for qualifying products. Key programs include Orphan Drug designation, Priority Review, SAKIGAKE, and Conditional/Time-Limited Approval.

Orphan Drug Designation

Japan's **Orphan Drug/Device Designation System** identifies medicines for rare diseases ($\leq 50,000$ patients) (www.mhlw.go.jp). Designation is granted by the MHLW based on medical need, often earlier in development. Incentives for designated orphan products include:

- **Priority Consultation:** Sponsors access expedited scientific advice sessions and reduced user fees for consultations (www.mhlw.go.jp).
- **PMDA Fee Reductions:** Lower fees for review and initial listing of designated drugs (www.mhlw.go.jp).
- **Subsidies and Support:** R&D subsidies through the National Institute of Biomedical Innovation to help defray development costs (www.mhlw.go.jp).
- **Tax Credits:** 12% tax credit on clinical study expenditure during orphan subsidy periods (www.mhlw.go.jp).
- **Extended Re-examination Period:** Once approved (via the usual NDA route), orphan drugs enjoy up to **10 years** before routine price re-evaluation (compared to 8 years for ordinary drugs) (www.mhlw.go.jp).
- **Priority Review:** Orphan drugs additionally qualify automatically for Japan's priority review (see below) (www.mhlw.go.jp).

Orphan designation itself does *not* guarantee approval – it simply triggers these supports. The actual review still requires demonstration of safety/efficacy (under one of the standard or expedited pathways).

Priority Review

Japan's **Priority Review (yūsen shinsa)** allows for shorter target review time (approx. 9 months instead of 12) (pmc.ncbi.nlm.nih.gov). To qualify, the drug must either have **no existing standard therapy** or show **superior clinical usefulness** (e.g. efficacy or safety) compared to alternatives; and it must treat a **serious disease or be an orphan** (pmc.ncbi.nlm.nih.gov). In practice, many cancer and rare-disease drugs receive this designation. PMDA works to published review-time targets (for context, the median approval time for all marketing authorisation applications in Japan was 332 days in 2023 (www.clinicaltrialsarena.com), roughly matching U.S. FDA).

SAKIGAKE Designation

Introduced in 2015, **SAKIGAKE** (a Japanese word meaning “pioneer” or “forerunner”) is Japan's version of a groundbreaking-therapy pathway similar to the FDA's Breakthrough Therapy. SAKIGAKE targets **novel medical products first developed in Japan**. Designated products receive **priority consultation** and a premarket review goal of approximately 6 months, roughly half the standard timeline (www.mhlw.go.jp). The four legal criteria for SAKIGAKE are (pmc.ncbi.nlm.nih.gov):

1. **Novel mechanism:** The drug should be innovative, in principle having a new mode of action.
2. **Serious indication:** Treats a serious disease (high mortality or few options).
3. **Prominent efficacy:** Demonstrates outstanding effectiveness in early trials.
4. **Japan-first submission:** Application is filed in Japan before any other country.

If all are met, MHLW designates the product as SAKIGAKE. This not only shortens the review clock (to as little as 6 months) but also brings regulatory support (frequent consults with PMDA review partners, planning team, etc.). As of May 2019, 22 drugs had been granted SAKIGAKE status (mostly from Japanese firms) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Examples include Nobelp's sirolimus for tuberous sclerosis (approved March 2017) and Shionogi's anti-influenza drug baloxavir ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Table 10 of Nagai et al. ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) lists these up to 2019.

Despite ambitious goals, actual performance varies. Some SAKIGAKE-designated products have achieved swift approvals (e.g. 9 months or less to decision), while others (notably some regenerative medicine products) remain pending or withdrawn if trials did not confirm efficacy. The unique Japan-first requirement means SAKIGAKE often benefits domestically-developed therapies. Recent designations demonstrate continued momentum: in December 2025, BlueRock Therapeutics' **bemdaneprocel** (BRT-DA01), a cell therapy for Parkinson's disease, received SAKIGAKE status (www.bluerocktx.com), and in January 2026, Nanoscope Therapeutics' **MCO-010**, an optogenetic gene therapy for inherited retinal dystrophies, received both SAKIGAKE and Orphan Drug designations. The program underscores Japan's strategy to make itself an attractive first-launch market for innovations meeting local needs.

Conditional Early Approval System

Japan's **Conditional Early Approval System** was launched by MHLW notification in 2017 and enshrined in law (effective September 2020) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). This pathway allows approval based on preliminary evidence when **confirmatory trials are impractical** and *if the drug addresses a serious unmet need*. Its four conditions ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) are:

1. **Serious disease:** e.g. life-threatening or irreversible condition.
2. **Proven clinical utility:** The drug must show significant efficacy in exploratory trials and few alternatives exist.
3. **Difficulty of confirmatory trials:** Due to rarity of disease or urgent need, large Phase III trials are deemed unfeasible or very prolonged.
4. **Reasonable expectation of benefit:** Clinical data (non-confirmatory) suggest the drug can offer adequate efficacy/safety.

When these are met, MHLW may grant conditional approval, and such applications automatically receive priority review ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). The approval comes with stringent *post-marketing obligations*. The sponsor must conduct post-approval surveillance and **confirmatory clinical studies** to verify the drug's benefit-risk profile. If follow-up trials fail to confirm efficacy, the product can be withdrawn.

By March 2020, four drugs had been approved under this system ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)), such as pembrolizumab for certain microsatellite-instability tumors and the exon-skipping drug viltolarsen for Duchenne muscular dystrophy ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). These cases illustrate the system: for example, viltolarsen was approved on surrogate endpoints (dystrophin expression) in a small uncontrolled study, with the condition that long-term efficacy be confirmed.

This conditional pathway is conceptually similar to **Accelerated Approval** in the U.S. and **Conditional Marketing Authorization** in the EU. It represents Japan's effort to provide early access for patients with dire needs, while still safeguarding against premature widespread use without validation. The system is still maturing; revisions in the 2025 PMD Act intend to broaden its applicability (allowing conditional approval at earlier stages of evidence generation) to spur innovation (insightplus.bakermckenzie.com).

Pediatric- and Strategy-Specific Initiatives

Japan has also enacted measures to encourage pediatric drug development. Recent reform mandates that marketing authorization holders file pediatric study plans for new drugs, aiming to avoid the gap seen in children's access. A new pediatric research fund will support development of child-appropriate formulations (insightplus.bakermckenzie.com). Additionally, Japan's **NIH-like funding** is coordinated by AMED (the Japan Agency for Medical Research and Development, established 2015) to bolster early-phase and rare-disease research.

Another important feature is **rapid price listing after approval**. Pricing is not negotiated during the approval review: once MHLW approves a drug, the NHI price is set through the Central Social Insurance Medical Council (Chuikyo) process, and the drug is typically listed with a price and covered by insurance within 60–90 days (www.clinicaltrialsarena.com). This accelerates patient access. In 2024, the government also implemented a major **pricing reform** to reward truly innovative drugs with premium pricing (biosector.jp), thereby aligning incentives with faster approvals and novel therapies.

In summary, Japan's expedited pathways mirror global trends but include Japan-specific features (e.g. SAKIGAKE's Japan-first rule). These mechanisms have become integral to the **PMDA review strategy**: by FY2024–25, PMDA reported 148 total drug approval decisions, of which 66 were new active ingredients (pharmaboardroom.com)—a testament to the regulatory push for innovation across standard and accelerated channels.

Regulatory Timelines and Statistical Analysis

Evaluating drug approval efficiency requires analyzing quantitative outcomes. In recent years, Japan has made significant strides in reducing approval times and shrinking historical lags. Several studies have documented these trends.

Number of Approvals and Drug Lag

Between 2008 and 2019, PMDA approved **400 new active substances** (NAS) (pmc.ncbi.nlm.nih.gov). Of these, 80 (20.0%) were **first-in-world approvals** granted in Japan (so-called “Japan-first” products) (pmc.ncbi.nlm.nih.gov). The remainder (80%) were first approved abroad (often U.S. or EU). Among global-first drugs, Japan's approval generally lagged behind U.S. FDA and EMA; however, this “drug lag” has shrunk over time.

Tanaka et al. reported that the **median drug lag** (the delay between first worldwide approval and Japanese approval) fell from about **4.3 years** during 2008–2011 to **1.3 years** in 2016–2019 ([pmc.ncbi.nlm.nih.gov](#)) ([pmc.ncbi.nlm.nih.gov](#)). In contrast, the lag for global-first approvals specifically fell from 4.7 years (2008–2011) to 2.2 years (2016–2019) ([pmc.ncbi.nlm.nih.gov](#)). These reductions coincide with PMDA initiatives to accelerate review and encourage simultaneous global filings. Notably, some therapeutic areas saw practically no lag by the 2010s (oncology, metabolic diseases, infectious diseases), while others (neurology, psychiatry) still exhibit multi-year delays ([pmc.ncbi.nlm.nih.gov](#)) ([pmc.ncbi.nlm.nih.gov](#)).

As evidence of progress, PMDA reported that in **FY2024–25 (Apr 2024–Mar 2025)** it issued 148 total approval decisions, of which 66 were new active ingredients and 82 were lifecycle expansions (new indications, pediatric expansions, formulation changes) ([pharmaboardroom.com](#)). Notable approvals spanned metabolic disease (icodec, tirzepatide/Zepbound), autoimmune conditions, rare pediatric disorders, and neurology (donanemab and Tauvid for Alzheimer's). For context, PMDA approved 80 new drugs in FY2019–20 and 88 in FY2020–21 ([pharmaboardroom.com](#)). These figures are internationally competitive: from 2008–2019, Japan approved 400 NAS versus 447 by FDA and 335 by EMA (Center for Innovation in Reg Science data) ([pmc.ncbi.nlm.nih.gov](#)). Thus Japan is no longer dramatically behind its peers in raw approval counts.

Review Timelines

Despite past lags, PMDA's review speed is now comparable to the US. In 2019, a comparison showed median approval times of **304 days in Japan, 243 days at FDA, and 423 days at EMA** ([pmc.ncbi.nlm.nih.gov](#)). Similarly, ClinicalTrialsArena reported a 2023 median review cycle of 332 days in Japan (vs 333 in the US and 453 in Europe) ([www.clinicaltrialsarena.com](#)). Japan's 9-month target for priority review ([pmc.ncbi.nlm.nih.gov](#)) and specialized programs like Sakigake have tightened these schedules. Priority review applications now routinely get decisions within 9–10 months (often faster in practice), whereas in the past they could extend a year or more.

Table 1 (above) summarizes the formal review targets in Japan, showing that its priority program is roughly in line with Western expedited tracks ([pmc.ncbi.nlm.nih.gov](#)) ([pmc.ncbi.nlm.nih.gov](#)). It is now common for sponsors to maintain ongoing dialogue with PMDA (via consultations) throughout development, smoothing final NDA review.

Therapeutic Area Distribution

Analysis of approval data by therapy reveals patterns. In Japan (2008–2019), the most active areas for new approvals were **oncology, metabolic/endocrine, and infectious diseases** ([pmc.ncbi.nlm.nih.gov](#)) ([pmc.ncbi.nlm.nih.gov](#)). These categories mirror global trends (breakthroughs in cancer immunotherapies, diabetes drugs, antivirals). They also produced the most Japan-first approvals (on the order of 17–35% Japan-first in those fields) ([pmc.ncbi.nlm.nih.gov](#)). By comparison, fields like **neurology and psychiatry**, with fewer new drugs developed globally and lower domestic R&D focus, showed very few Japan-first entries and still substantial lag (median >5 years ([pmc.ncbi.nlm.nih.gov](#))).

Figures from Tanaka et al. show that of the 400 NAS approvals, oncology led with ~67 (16.8%), followed by metabolic (like diabetes/osteoporosis) at ~47 (11.8%), and infectious diseases (HCV, HIV, bacterial agents) at ~46 (11.5%). The median drug lag in infectious diseases by the late 2010s was already under 1 year for most,

whereas neurology's lag remained around 5+ years ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). This has important implications: many life-saving therapies (e.g. hepatitis C antivirals, immunooncology drugs) reached Japanese patients nearly as quickly as in the West, but schizophrenia or MS medications did not.

First-in-World Approvals

Japan's share of first-in-world (FIW) approvals is noteworthy. Tanaka et al. found ~20% FIW among NAS approvals during 2008–2019 ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). This percentage has slowly increased thanks to initiatives like Sakigake and increased domestic biotech activity. Most Japan-first drugs (like several DMD exon-skipping or rare disease therapies) were developed by Japanese companies (over 80% of domestic company submissions led to global approvals ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov))). The proportion of Japan-first remained low (~10%) among global-approved products, highlighting that many FIW approvals in Japan occur on “local-approval” products that have not been filed elsewhere ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)).

Tanaka et al. tracked how Japan-first approvals and drug lag changed across 2008–2019 ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). This reflects both domestic innovation and strategic global development (e.g. sponsors filing in Japan in parallel with the U.S., as with lecanemab, approved in Japan in September 2023, about two and a half months after its U.S. approval (www.eisai.com)). Importantly, the study found no evidence that approving drugs first-in-Japan compromised safety: the rate of post-market safety alerts (Blue Letters) was similar between Japan-first and global-first products ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)).

Comparator and Trend Analysis

For further data, we note that from a user perspective, average approval times include both review and any gaps. Beyond median times, studies have analyzed factors affecting quick approval. For instance, analyses suggest that domestic Japanese companies tend to submit earlier, reducing delay compared to foreign sponsors ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Multi-regional trials with Japanese sites strongly shorten development lag ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Projected continuation of these trends suggests Japan may soon achieve simultaneous global launches in more cases.

On the financial side, stakeholders often cite the pricing code as a key influence. Tokyo Foundation's analysis (Sept 2024) highlighted that aggressive biennial price cuts and strict reference pricing have discouraged companies from focusing on Japan (www.tokyofoundation.org) (www.tokyofoundation.org). While pricing is outside the formal “approval process,” it affects strategic decisions to even file in Japan. For example, it was reported that several fast-growing biopharma companies omitted Japanese submissions for high-value drugs, citing the complex regulatory/price environment (www.tokyofoundation.org).

To summarize, **quantitative trends show that PMDA's review speed has improved to Western levels, and the proportion of Japanese innovations (or simultaneous launches) is rising.** However, Japan still wrestles with ensuring equitable access across all disease areas and maintaining attractiveness for global sponsors.

Clinical Trial Environment and Considerations

Japan's unique healthcare and research environment imposes both advantages and challenges on drug development.

Infrastructure and Workforce

Japan's population (≈125 million) has widespread healthcare coverage: nearly **universal national health insurance** provides clinicians and patients broad access to therapies. This means many potential trial participants already receive standard treatments, which can complicate placebo-controlled trials (patients often unwilling to forego therapy) and may require trial designs with active comparators or add-on designs. Moreover, Japanese medical institutions are numerous (as noted by CMIC: “eight times more hospitals than the UK” by headcount (www.clinicaltrialsarena.com), reflecting a decentralized hospital system). This large network can yield diverse patient pools, but it also means investigators and ethics committees are fragmented, leading to slower multi-center coordination.

Efforts are underway to centralize ethics review (shared IRBs) in some regions to streamline this aspect (www.clinicaltrialsarena.com). Language and cultural factors also matter: all trial materials (protocol, consent forms) must be in Japanese. This necessitates translation and local validation of endpoints and instruments, which adds time and cost relative to purely English-speaking contexts. On the other hand, Japanese sites are known for high-quality data and compliance (FDA audits from 2009–2023 found few compliance issues in Japan (www.clinicaltrialsarena.com)). Investigators are generally well trained, and adherence to protocols tends to be strong, reflecting Japan's emphasis on precision and structure.

Role of SMOs and CROs

As mentioned, **Site Management Organizations (SMOs)** are a distinctive element. Many hospitals rely on SMOs to manage research nursing and coordination tasks (www.clinicaltrialsarena.com). By financial year 2023, 70% of Japanese trial sites contracted with SMOs (www.clinicaltrialsarena.com). SMOs help with IRB submissions, patient recruitment (especially important in rare disease trials), and logistics. CDM (clinical data management) work is mostly performed by contract research organizations (CROs). Major global CROs maintain Japanese branches or partners to handle local regulatory interactions.

Cost and Patient Recruitment

Trials in Japan are sometimes considered more expensive than in comparable countries. Factors include high hourly wages for healthcare staff, and elaborate monitoring requirements. However, Japan's controlled healthcare system (single-payer, price negotiations, limited litigation) also means that once approved, broad reimbursement is easier to obtain. Hence some sponsors accept higher upfront trial costs in exchange for broad reimbursement.

Recruitment can be lengthy if only local patients are eligible, due to Japan's smaller share of some disease populations. Multinational trials are thus key: recent guidelines encourage including Japanese patients in global MRCTs. Post-2023 rules allow bypassing a pre-MRCT Phase I (as above ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/))), meaning Japan can join global Phase IIb/III trials concurrently with the West if criteria are met. This is expected to help accelerate access.

Specific Challenges

Some regulatory peculiarities still require adjustment by sponsors. For example, Japan's **two-week prescription rule** limits prescriptions of newly launched drugs to a two-week supply during their first year on the NHI price list; the Tokyo Foundation describes it as obsolete because it has required companies to produce Japan-only packaging (www.tokyoofoundation.org). Similarly, the requirement for all-case surveillance or extensive post-marketing studies (often required for drugs approved in accelerated pathways) can deter some companies concerned about liability.

Additionally, differences in **disease prevalence** mean that some globally common illnesses have relatively few Japanese patients (e.g. multiple sclerosis, certain cancers) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)). A Japanese participant population must be sufficient to satisfy trial endpoints, sometimes requiring sponsor investment in local patient registries or long recruitment periods. This epidemiological gap is most evident in fields where Japanese companies traditionally have low R&D focus (neurology/psychiatry).

Overall, while Japan's market has clear merits (strong intellectual property protections, centralized listing, and a culture of pharma innovation), its trial environment is less facilitator-friendly than in, say, Singapore or Australia. Recent regulatory changes (CTD English allowance, streamlined IRB, pharma associations educating global CROs) aim to mitigate these barriers.

Case Studies and Real-World Examples

Concrete examples illustrate how Japan's system works in practice and how innovative products have navigated it.

Alzheimer's Disease – Lecanemab (Leqembi)

A prominent recent case is **lecanemab** (Eisai/Biogen) for early Alzheimer's disease. This humanized monoclonal antibody targeting amyloid-beta was approved in the U.S. (as *Leqembi*) in July 2023 after positive Phase III outcomes. Japan's MHLW granted approval in September 2023, just two months later, making Japan the second country to approve (www.eisai.com). This was achieved via priority review ("designated for priority review in January 2023" (www.eisai.com)), reflecting Japan's expedited pathway readiness.

Key regulatory points in this case:

- **Global Trial Data:** The NDA relied on the Clarity AD global trial (over 1,700 subjects) (www.eisai.com). Japanese authorities accepted foreign efficacy/safety data because the trial included Japanese and similar Asian cohorts, aligning with ICH E5 principles.

- **Priority Review:** Lecanemab met priority criteria (severe unmet need, novel MOA). PMDA finished review within ~9 months.
- **Conditional / Post-Marketing Requirements:** MHLW imposed **all-case surveillance** on all patients receiving lecanemab, per approval conditions (www.eisai.com). This means the company must actively follow every treated patient to monitor real-world outcomes. Eisai publicly committed to conduct this survey until a set number of patient-years are accumulated (www.eisai.com).
- **Insurance Listing:** NHI price listing followed approval through the standard post-approval process: lecanemab was listed on the NHI price list in December 2023, about three months after approval. Eisai also announced the development of physician training for managing amyloid-related imaging abnormalities (ARIA) (www.ipharmacenter.com) (www.eisai.com), as required by PMDA.
- **Patient Access:** The rapid approval (second in world) exemplified Japan's ability to deliver a breakthrough therapy swiftly once regulatory and commercial processes aligned. It followed extensive public outreach by Eisai (awareness of ARIA, for example) to Japanese neurologists and insurers, showcasing industry-regulator collaboration.

This example underscores several facets of Japan's system: global trial integration, expedited review, stringent post-market surveillance, and coordinated pricing. It also highlights Japan's willingness to follow US/EMA lead when evidence is clear. Notably, in **September 2023**, Eisai's approval announcement stated "we believe that we have turned a new page in the history of Alzheimer's disease treatment" (www.eisai.com) – reflecting the product's significance and Japan's regulatory responsiveness.

Building on lecanemab's success, Eli Lilly's **donanemab** (Kisunla) received Japanese approval in **September 2024**, making Japan one of the first countries alongside the U.S. to approve this second anti-amyloid therapy. MHLW issued Optimal Use Guidelines for donanemab in November 2024, mirroring appropriate use recommendations while adding NHI-specific requirements. Real-world adoption data show approximately 6,000 patients were treated with lecanemab in the first year post-launch, with 79% of specialists reporting wait times of 3 months or less from first consultation to initial infusion ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). In 2025, Eisai also filed an NDA for a subcutaneous autoinjector formulation of lecanemab, seeking to improve convenience for Japanese patients (www.eisai.com).

Oncology – Gilteritinib and Pembrolizumab

In oncology, **gilteritinib** (Astellas/ASP2215) and **pembrolizumab** (Merck/MSD) illustrate priority and Sakigake dynamics. Gilteritinib, an FLT3 inhibitor for relapsed acute myeloid leukemia, was SAKIGAKE-designated in 2015 and approved by PMDA in September 2018 ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) (NDA filing was Japan-first in 2017). This marked a case where a Japanese company took global lead. Pembrolizumab's advanced gastric cancer indication was also SAKIGAKE-designated (October 2015), but Nagai's 2019 table lists the designation as *declined*, with no marketing authorization ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) This illustrates that SAKIGAKE designation does not guarantee approval without data.

Another example: **nivolumab (Opdivo)** for cholangiocarcinoma (a biliary tract cancer). Ono Pharmaceutical's product was SAKIGAKE-designated for this indication in April 2017, but Nagai's 2019 table records no marketing authorization for it ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)).

These oncology cases highlight Japan's emphasis on novel targets. They also demonstrate the rigorous follow-up: even with SAKIGAKE, PMDA will not approve unless data justify it (unlike an automatic fast-track). They reinforce that Japan can both champion global-first filings (gilteritinib) and hold companies to high evidence standards.

Rare Disease – Viltolarsen (Duchenne Muscular Dystrophy)

Viltolarsen, developed by Nippon Shinyaku, is an antisense oligonucleotide for Duchenne muscular dystrophy (exon 53 skipping). It is an instructive success for Japan-first development: initial filing in Japan was followed by U.S. submission later. Viltolarsen obtained approval in Japan under the Conditional Early Approval System in March 2020, based on surrogate endpoint data from a small uncontrolled trial ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32411111/)). The US followed with accelerated approval in August 2020 (under the name *Viltepso*). This drug illustrates:

- A Japanese company developing a therapy for patients whose DMD mutations are amenable to exon 53 skipping.
- Use of conditional approval: MHLW granted it on dystrophin increase (primary endpoint, Table 2 ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32411111/))), with post-approval requirements (the company must conduct larger confirmatory studies as mandated by PMDA).
- Demonstrates Japan's willingness to approve novel RNA therapies (one of the first approvals of its kind globally) with limited patient numbers.

Though the viltolarsen case is somewhat well-known in biotech circles, peer-reviewed sources from Japan (e.g. Komaki et al.) focus on clinical aspects ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32411111/)). However, regulatory commentary notes it as a case of Sakigake/conditional success.

Emerging Therapies and Other Modalities

Japan has also approved *advanced therapies*. PMDA lists Novartis's **Kymriah (tisagenlecleucel)** with an initial approval in March 2019 and Kite's **Yescarta (axicabtagene ciloleucel)** with an initial approval in January 2021. PMDA classifies both as regenerative medical products. PMDA also lists **TEMCELL** as a human **allogeneic** bone-marrow-derived mesenchymal stem-cell product, approved in September 2015; it should not be described as autologous. These examples illustrate the separate regulatory category for regenerative medical products under Japan's PMDA Act.

In summary, these case studies illustrate Japan's application of both standard and special approval mechanisms. Common themes are global clinical trial reliance, expedited review, and strict post-market conditions. They also underscore that Japan often makes regulatory decisions within months of the US/EU in high-profile cases, countering the old narrative that Japan invariably lags by years.

Discussion of Challenges and Implications

While recent reforms have boosted Japan's regulatory performance, several challenges and broader implications remain.

Persistent Drug Lag and Loss

Despite gains, **drug lag and loss** remain concerns (www.tokyofoundation.org). As of 2024, dozens of first-in-world medicines identified by MHLW were still not launched in Japan (www.tokyofoundation.org). Factors include: (1) **Pricing Policy**. Biennial price cuts (often 7–20%) and reference pricing (new-drug prices set relative to existing comparators, with low Japanese prices also referenced by some other countries such as South Korea and Taiwan) have reduced economic incentives (www.tokyofoundation.org). High launch costs and recycling lower revenues mean some sponsors deprioritize Japan. The Tokyo Foundation also notes that supply allocation of certain vaccines and GLP-1 agonist products often favored the US market first for financial reasons (www.tokyofoundation.org). The 2024 drug pricing reform aimed to address this by awarding larger premiums for truly innovative therapies, and the December 2025 FY2026 pricing revision draft further attempted to reduce ambiguity in price maintenance programs and increase opportunities for NHI pricing designation from four to seven times annually (pj.jiho.jp). However, industry sentiment remains mixed: the Japan Pharmaceutical Manufacturers Association (JPMA) issued a December 2025 joint statement warning that continued excessive reliance on drug price cuts for fiscal savings discourages innovation investment (www.jpma.or.jp). Notably, Tokyo Foundation reported that the combined effect of pricing and shifting global innovation is profound: only ~4% of global new trials are initiated by Japan-based companies, reflecting Japan's diminished position in cutting-edge R&D (www.tokyofoundation.org) (www.tokyofoundation.org).

(2) **Clinical Trial Barriers**. The requirement for Japanese-specific data, though relaxed in late 2023 (pmc.ncbi.nlm.nih.gov), was historically a deterrent, especially for small biotech firms. Language barriers and sponsor unfamiliarity with local rules (e.g. IRB landscape) also dissuade some companies. The multi-investigator-as-sponsor GCP structure means global companies must negotiate complex legal sponsorship designs for Japan. That said, the new guideline allowing sponsors to forgo a pre-MRCT study in appropriate circumstances may help more companies include Japan from Phase II onward (www.clinicaltrialsarena.com).

(3) **Regulator Perceptions**. Anecdotally, Japanese review was once seen as bureaucratic or risk-averse. PMDA engages with overseas regulators on international initiatives, but it is not a Project Orbis Partner. FDA's published Project Orbis Partner list does not include PMDA.

Balancing Speed and Safety

There is an inherent tension between faster approvals and assuring safety. Critics of accelerated pathways warn of premature market entry. Japan has responded by coupling speed with rigorous follow-up. For example, **no Japan-first approval in 2008–2019 was later withdrawn for safety reasons** more often than others (pmc.ncbi.nlm.nih.gov). Moreover, the frequency of serious post-approval safety alerts ("Blue Letters") was low (2–3% of approvals) and similar for Japan-first and global-first drugs (pmc.ncbi.nlm.nih.gov). This suggests that rapid approval has not compromised safety. The conditional approval framework explicitly binds companies to confirm benefit post-launch, aligning incentives.

Going forward, ensuring this balance will require ongoing regulatory vigilance. Postmarketing surveillance in Japan now heavily utilizes electronic data capture from insurance records and hospital registries. PMDA is also promoting greater patient engagement (the "patient-focused drug development" program mentioned by Tanaka

([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) to better understand risk–benefit from patients’ perspectives.

Harmonization and Global Development

The globalization of drug development means Japan participates more in MRCTs. ICH M4 CTD standardization, ICH E6 GCP harmonization, and ICH E17 (multi-reg trial guidance) all facilitate multinational submissions. The PMDA increasingly accepts foreign data at face value if scientifically justified (e.g. bridging studies, use of global trial subsets). PMDA's Washington D.C. Office (opened November 2024, its second overseas office after a Thailand-based Asia office opened in July 2024) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) (www.pmda.go.jp) exemplifies outreach to U.S. pharma: the office operates entirely in English, provides regulatory consultations, and collaborates with JETRO and AMED to support U.S. startups entering Japan (idec-inc.com). Japan also cooperates with Asian regulators (e.g. ASEAN/Japan consultations) to extend data utility regionally.

However, not all is frictionless. Certain ICH guidelines (like pediatric requirements E11) have had slower uptake in Japan, though they are now fully applied. Cost-effectiveness analysis (health economics) is another area where Japan is diverging – not in the approval process per se but in subsequent pricing (recently implemented). Over time, the line between “approval” and “access” may blur as price negotiations consider a therapy’s societal value.

Future Directions

Several trajectories are worth noting for the coming years:

- **Regulatory Science and Innovation:** Japan is investing in regulatory science (through PMDA’s offices and external university partnerships) to preemptively address emerging modalities (gene editing, digital therapeutics, AI-generated evidence). For instance, PMDA participated in ICH discussions on digital endpoints (e.g. wearables). PMDA set **April 1, 2026** for the full-scale implementation of **eCTD v4.0** electronic submissions, ahead of other major regulators’ timelines for this metadata-driven format (japan.freyrsolutions.com), signaling Japan’s leadership in digital regulatory infrastructure.
- **Continuous Improvement:** The 2025 PMD Act amendments, enacted on **May 14, 2025** (insightplus.bakermckenzie.com), signal Japan’s commitment to evolve. Phased implementation is scheduled over the following three years (by May 2027 at latest). Key elements – mandated quality managers (the *Sekinin Yakuin* provisions now authorize MHLW to order replacement of board members who fail to prevent public health risks), supply chain oversight (including new Supply Chain Management Officers), flexible approval-change processes, and pediatric plans – all aim to modernize infrastructure (www.nishimura.com). The new supply stability requirements (e.g. shipping-notification, national stockpiles) recognize that drug approval is hollow if medications cannot reach patients. MHLW also issued 15 implementing notices ahead of the amendment’s phased rollout (pj.jiho.jp).
- **Patient Centricity:** Japan’s regulators are emphasizing the patient voice. PMDA’s “Patient-Focused Drug Development Program” solicits patient group input early in pharma development and review. The idea is to ensure that endpoints and risk tolerances reflect Japanese patient populations. While still

nascent, this shift mirrors global trends and may alter review priorities over time.

- **International Collaboration:** Japan continues to deepen multi-country regulatory engagement. PMDA is not a formal FDA Project Orbis Partner; FDA lists Australia, Brazil, Canada, Israel, Singapore, Switzerland, and the United Kingdom as Project Orbis Partners. The opening of PMDA's Washington, D.C., and Bangkok offices in 2024 marks its first-ever overseas presence, designed to attract U.S. and Asian sponsors into the Japanese market. Joint data pools (e.g. for orphan diseases) may help overcome small patient numbers. Additionally, coordination on regulatory labels could reduce duplicative legal requirements.
- **Enhancing Clinical Trial Ecosystem:** Within Japan, proposals exist to simplify sponsor responsibilities, aggregate IRB approvals, and reduce translation burdens. The new Clinical Trials Act (2018) made trial conduct more transparent but added layers of regulation for academics. Future adjustments (such as streamlining low-risk investigator-initiated trials) may be debated to encourage domestic research. If more first-in-human studies start in Japan, this could help reduce the historical “lag.”
- **Real-World Data and Digital Trials:** Although still early, Japan is exploring use of electronic health records and claims data for post-market monitoring and even regulatory submissions. With workforce aging, remote trials and telemedicine data are likely to grow, hopefully accelerated by lessons learned in the pandemic. Regulatory frameworks for digital health products (e.g. smartphone apps for mental health) are also under development, potentially integrated with drug approvals (combination products).

Conclusion

Japan's drug approval process has made remarkable progress from its earlier era of multi-year delays. Through targeted reforms, infrastructure investment, and global harmonization, PMDA and MHLW now process many new drug applications almost as quickly as Western regulators ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) (www.clinicaltrialsarena.com). Expedited pathways (priority review, SAKIGAKE, conditional approval) specifically designed for urgent unmet needs have expanded patient access to innovations. Statistical analyses confirm that median approval times and drug lag have both significantly decreased in the 2010s ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) (www.clinicaltrialsarena.com).

However, challenges remain. Not all patients benefit equally: therapeutic areas with limited R&D face ongoing delays ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). The threat of Japan being bypassed (“drug loss”) persists unless the ecosystem becomes more attractive to international developers (www.tokyofoundation.org) (www.tokyofoundation.org). Aging demographics and high healthcare costs also strain the system, requiring efficient and sustainable pricing.

Looking ahead, the PMD Act amendments enacted in May 2025 are being phased in through 2027, promising to further strengthen Japan's regulatory infrastructure: by codifying quality control roles, enhancing supply chain resilience, expanding conditional approval to earlier-stage evidence, and incentivizing breakthrough and pediatric therapies (insightplus.bakermckenzie.com) (insightplus.bakermckenzie.com). Japan's regulators are positioning themselves as global partners in innovation: PMDA's overseas offices in Washington, D.C., and Bangkok and the April 2026 move to eCTD v4.0 demonstrate a regulator actively modernizing to attract international sponsors and accelerate patient access.

The evidence suggests Japan has achieved a new equilibrium: not the slowest reviewer in the world, but a mature regulator that still retains a cautious commitment to safety. In the words of Tanaka et al., “Drug lag has been significantly decreased, although it still exists” ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)), and Japan’s first-in-world approvals now constitute a meaningful fraction of all new drugs (20%). The task now is nuanced: to extend these gains to underserved areas, to ensure that accelerated access does not compromise quality, and to maintain international collaboration in a complex global drug landscape.

For researchers, industry, and policymakers, Japan’s example offers a valuable case study in balancing national priorities with globalization. It shows that even after decades of lag, a well-funded, focused reform effort can yield substantial improvements. Future studies will need to continue monitoring outcomes – such as real-world patient benefit and safety – to ensure that regulatory agility always aligns with public health.

This report draws on sources linked inline and listed in the references. It aims to provide an evidence-based overview of Japan’s drug regulatory pathway as of early 2026, including both its achievements and areas for further evolution.

References

- Tanaka et al., *Clin Pharmacol Ther* 2020 ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)).
- Matsushita et al., *Clin Transl Sci* 2021 ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)).
- Nagai, *Int J Mol Sci* 2019, Tables 1 & 10 ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)).
- Fukuhara et al., *Clin Transl Sci* 2025 ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)).
- PMDA official materials (e.g. SAKIGAKE press release) (www.mhlw.go.jp).
- Baker McKenzie (Tokyo) 28 May 2025 (insightplus.bakermckenzie.com) (insightplus.bakermckenzie.com).
- PMDA/JPMA news (FY2024–25 approvals) (pharmaboardroom.com).
- Eisai press release (Lecanemab Sep 2023) (www.eisai.com) (www.eisai.com).
- ClinicalTrialsArena, Aug 2024 (www.clinicaltrialsarena.com) (www.clinicaltrialsarena.com).
- MHLW orphan drug guidance (www.mhlw.go.jp) (www.mhlw.go.jp).
- Tokyo Foundation analysis, Sept 2024 (www.tokyofoundation.org) (www.tokyofoundation.org).
- PMDA history page (www.pmda.go.jp) (PMDA establishment).
- Clinical trials regulatory summary (Nakamura JSCO 2020) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34811111/)).
- Overview of Japan’s Pharmaceuticals and Medical Devices Act (Monolith Law Office) (monolith.law).
- JPMA Joint Statement on FY2026 NHI Drug Pricing Reform, Dec 2025 (www.jpma.or.jp).
- Nishimura & Asahi, 2025 Amendments to PMD Act (www.nishimura.com).
- PMDA Washington D.C. Office (www.pmda.go.jp).

- BlueRock bemdaneprocel SAKIGAKE designation, Dec 2025 (www.bluerocktx.com).
- Real-world lecanemab adoption in Japan, 1 year post-launch (pmc.ncbi.nlm.nih.gov).
- Eisai subcutaneous lecanemab NDA, 2025 (www.eisai.com).
- Japan eCTD v4.0 mandate, Apr 2026 (japan.freyrsolutions.com).

(References are inline using broad page ranges for readability.)

Source links

Links cited in this article, in order of first appearance. Full addresses are provided for readers using extracted text.

1. <https://intuitionlabs.ai/articles/drug-development-pipeline-guide>
2. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8246743/>
3. <https://www.pmda.go.jp/english/about-pmda/outline/0002.html>
4. <https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/170421-01.html>
5. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8212755/>
6. <https://intuitionlabs.ai/articles/ich-e6-r3-gcp-guidelines-2025>
7. https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html
8. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6696404/>
9. <https://intuitionlabs.ai/articles/target-trial-emulation-rwe>
10. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12092971/>
11. <https://www.clinicaltrialsarena.com/news/japan-offers-competitive-edge-with-clinical-trial-landscape-and-smo-approach/>
12. <https://insightplus.bakermckenzie.com/bm/healthcare-life-sciences/japan-overview-of-the-2025-pmd-act-amendment/>
13. <https://pharmaboardroom.com/articles/japan-pmda-shoots-ahead-in-fy-2024%E2%80%99125-with-148-drug-approvals/>
14. <https://www.tokyofoundation.org/research/detail.php?id=978>
15. <https://pj.jiho.jp/article/254857>
16. <https://japan.freyrsolutions.com/blogs/ectd-v4-0-in-japan-navigating-the-2026-regulatory-transformation>
17. <https://intuitionlabs.ai/articles/cognition-therapeutics-pipeline-analysis>
18. <https://intuitionlabs.ai/articles/pharmaceutical-market-analysis-trends>
19. https://www.mhlw.go.jp/www1/english/wp_5/vol1/p2c6s3.html
20. <https://monolith.law/en/general-corporate/pharmaceuticals-law>
21. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7160916/>
22. <https://www.bluerocktx.com/bluerock-therapeutics-investigative-cell-therapy-bemdaneprocel-for-treating-parkinsons-disease-receives-pioneering-regenerative-medical-product-designation-in-japan/>
23. <https://biosector.jp/japans-drug-regulation-overhaul-your-golden-opportunity/>
24. <https://www.eisai.com/news/2023/news202359.html>
25. <https://www.ipharmacenter.com/post/japan-drug-approvals-2023-mhlw-pmda-ipharmacenter>
26. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12536362/>

27. <https://www.eisai.com/news/2025/news202582.html>
28. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7732240/>
29. <https://pj.jiho.jp/article/254494>
30. https://www.jpma.or.jp/english/news_room/release/news2025/251216.html
31. <https://www.pmda.go.jp/english/int-activities/overseas-office/dc/0001.html>
32. <https://idec-inc.com/blog/2024/12/16/pmda-washington-office-begins-operations-building-bridges-for-u-s-startups-to-japan/>
33. https://www.nishimura.com/en/knowledge/newsletters/lifesciences_healthcare_251022
34. <https://pj.jiho.jp/article/254853>

THE PUBLISHER

About IntuitionLabs

IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.

AI consulting and adoption

Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.

Software, data and life-science workflows

IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.

Enterprise platforms and regulated delivery

We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.

Work with IntuitionLabs

Explore [AI enablement](#), [pharma and biotech software development](#), [data engineering and BI](#), and [Veeva services](#). [Contact IntuitionLabs](#) to discuss your workflow, information sources and implementation needs.

IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.

Website: <https://intuitionlabs.ai>

This article is educational. Verify consequential medical, legal, financial, regulatory and technical decisions with appropriate professionals and the cited primary sources. Company services are described separately from the article's research findings.